Insider · CIK 0001131146
Stephen Davis
Files at HRTX (HERON THERAPEUTICS, INC. /DE/), ACAD (ACADIA PHARMACEUTICALS INC), BLCM (BELLICUM PHARMACEUTICALS, INC). First filing Oct 18, 2022, latest Aug 20, 2024.
In brief
Stephen Davis files SEC Form 4 as CEO and director at ACAD (ACADIA PHARMACEUTICALS INC), and also at HRTX (HERON THERAPEUTICS, INC. /DE/), BLCM (BELLICUM PHARMACEUTICALS, INC). Since Oct 18, 2022, Stephen Davis has reported 0 open-market buys worth $0 and 11 open-market sells worth $2.2M, the latest filed on Aug 20, 2024.
A track record needs three past buys with six months of prices behind them; Stephen Davis has 0, so none is measured yet.
The newest scored trade: sold $485k of ACAD on Aug 19, 2024, filed Aug 20, 2024, scored 43 (moderate), under a 10b5-1 plan.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ACAD: ACADIA PHARMACEUTICALS INC
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | ACADIA PHARMACEUTICALS INC | $485k 31,747 shares | -15% | +8% from low-50% from high | |
| 17Weak | ACADIA PHARMACEUTICALS INC | $194k 11,427 shares | -7% | +5% from low-49% from high | |
| 27Weak | ACADIA PHARMACEUTICALS INC | $475k 26,574 shares | -16% | +0% from low-47% from high | |
| 39Weak | ACADIA PHARMACEUTICALS INC | $317k 17,714 shares | -13% | +2% from low-46% from high | |
| 16Weak | ACADIA PHARMACEUTICALS INC | $138k 5,577 shares | -5% | +46% from low-23% from high | |
| 35Weak | ACADIA PHARMACEUTICALS INC | $112k 3,732 shares | -4% | +79% from low-10% from high | |
| 36Weak | ACADIA PHARMACEUTICALS INC | $165k 7,806 shares | -7% | +67% from low0% from high | |
| 36Weak | ACADIA PHARMACEUTICALS INC | $156k 8,582 shares | -8% | +41% from low-33% from high | |
| 33Weak | ACADIA PHARMACEUTICALS INC | $72k 3,851 shares | -4% | +45% from low-30% from high | |
| 33Weak | ACADIA PHARMACEUTICALS INC | $67k 3,904 shares | -4% | +30% from low-39% from high | |
| 24Weak | ACADIA PHARMACEUTICALS INC | $44k 2,804 shares | -3% | +21% from low-43% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 14, 2023 | ACAD ACADIA PHARMACEUTICALS INC | 100,000 0.06% of outstanding | $2.6M | Jul 14, 2023 | $543k |
| Jul 13, 2023 | ACAD ACADIA PHARMACEUTICALS INC | 71,602 0.04% of outstanding | $1.8M | Jul 11, 2023 | none |
Transactions
Every row this insider has filed, 41 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 16, 2024 | ACAD ACADIA PHARMACEUTICALS INC | AGrant or award Common Stock | +17,333 | $0.00 | $0 | 173,520 | Aug 20, 2024 |
| Aug 16, 2024 | ACAD ACADIA PHARMACEUTICALS INC | AGrant or award Common Stock | +44,782 | $0.00 | $0 | 218,302 | Aug 20, 2024 |
| Aug 19, 2024 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -31,747 | $15.28 | $485k | 186,555 | Aug 20, 2024 |
| May 1, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +22,391 | - | - | 166,658 | May 3, 2024 |
| May 2, 2024 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -11,427 | $16.94 | $194k | 155,231 | May 3, 2024 |
| May 1, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -22,391 | $0.00 | $0 | 67,173 | May 3, 2024 |
| Apr 5, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +17,333 | - | - | 136,175 | Apr 9, 2024 |
| Apr 5, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +34,666 | - | - | 170,841 | Apr 9, 2024 |
| Apr 8, 2024 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -8,858 | $17.87 | $158k | 161,983 | Apr 9, 2024 |
| Apr 8, 2024 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -17,716 | $17.87 | $317k | 144,267 | Apr 9, 2024 |
| Apr 5, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -17,333 | $0.00 | $0 | 34,667 | Apr 9, 2024 |
| Apr 5, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -34,666 | $0.00 | $0 | 138,666 | Apr 9, 2024 |
| Mar 25, 2024 | ACAD ACADIA PHARMACEUTICALS INC | AGrant or award Common Stock | +34,666 | $0.00 | $0 | 136,556 | Mar 27, 2024 |
| Mar 27, 2024 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -17,714 | $17.90 | $317k | 118,842 | Mar 27, 2024 |
| Mar 25, 2024 | ACAD ACADIA PHARMACEUTICALS INC | AGrant or award Stock Option (Right to Buy)derivative | +286,451 | $0.00 | $0 | 286,451 | Mar 27, 2024 |
| Feb 23, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +10,946 | - | - | 107,467 | Feb 27, 2024 |
| Feb 26, 2024 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock10b5-1 | -5,577 | $24.67 | $138k | 101,890 | Feb 27, 2024 |
| Feb 23, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -10,946 | $0.00 | $0 | 10,946 | Feb 27, 2024 |
| Jan 6, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +9,528 | - | - | 100,253 | Jan 9, 2024 |
| Jan 8, 2024 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock | -3,732 | $29.96 | $112k | 96,521 | Jan 9, 2024 |
| Jan 6, 2024 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -9,528 | $0.00 | $0 | 0 | Jan 9, 2024 |
| May 1, 2023 | ACAD ACADIA PHARMACEUTICALS INC | AGrant or award Stock Options (Right to Buy)derivative | +295,503 | $0.00 | $0 | 295,503 | May 3, 2023 |
| May 1, 2023 | ACAD ACADIA PHARMACEUTICALS INC | AGrant or award Restricted Stock Unitsderivative | +89,564 | $0.00 | $0 | 89,564 | May 3, 2023 |
| Apr 29, 2023 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +15,625 | $0.00 | $0 | 116,103 | May 2, 2023 |
| May 1, 2023 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock | -7,806 | $21.18 | $165k | 108,297 | May 2, 2023 |
| Apr 29, 2023 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -15,625 | $0.00 | $0 | 0 | May 2, 2023 |
| Apr 5, 2023 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +17,333 | - | - | 109,060 | Apr 7, 2023 |
| Apr 6, 2023 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock | -8,582 | $18.16 | $156k | 100,478 | Apr 7, 2023 |
| Apr 5, 2023 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -17,333 | $0.00 | $0 | 52,000 | Apr 7, 2023 |
| Feb 23, 2023 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +10,945 | - | - | 95,578 | Feb 27, 2023 |
| Feb 24, 2023 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock | -3,851 | $18.78 | $72k | 91,727 | Feb 27, 2023 |
| Feb 23, 2023 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -10,945 | $0.00 | $0 | 21,892 | Feb 27, 2023 |
| Jan 6, 2023 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +9,528 | - | - | 88,537 | Jan 10, 2023 |
| Jan 9, 2023 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock | -3,904 | $17.13 | $67k | 84,633 | Jan 10, 2023 |
| Jan 6, 2023 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -9,528 | $0.00 | $0 | 9,528 | Jan 10, 2023 |
| Jan 3, 2023 | BLCM BELLICUM PHARMACEUTICALS, INC | MOption exercise Common Stock | +74,739 | $0.00 | $0 | 136,854 | Jan 5, 2023 |
| Dec 16, 2022 | HRTX HERON THERAPEUTICS, INC. /DE/ | AGrant or award Common Stock | +38,580 | $0.00 | $0 | 52,032 | Dec 20, 2022 |
| Dec 16, 2022 | HRTX HERON THERAPEUTICS, INC. /DE/ | AGrant or award Stock Option (Right to Buy)derivative | +77,160 | $0.00 | $0 | 77,160 | Dec 20, 2022 |
| Oct 15, 2022 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Common Stock | +5,938 | - | - | 81,813 | Oct 18, 2022 |
| Oct 15, 2022 | ACAD ACADIA PHARMACEUTICALS INC | SOpen-market sale Common Stock | -2,804 | $15.81 | $44k | 79,009 | Oct 18, 2022 |
| Oct 15, 2022 | ACAD ACADIA PHARMACEUTICALS INC | MOption exercise Restricted Stock Unitsderivative | -5,938 | $0.00 | $0 | 0 | Oct 18, 2022 |
Questions about Stephen Davis
Answered from the filings on this page, as of the latest one.
Is Stephen Davis buying or selling?
Not in the last 12 months. Stephen Davis's latest open-market trade on SEC Form 4 was sold $485k of ACAD on Aug 19, 2024.
How did Stephen Davis's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Stephen Davis has 0.
Where does Stephen Davis file Form 4?
Stephen Davis has filed Form 4 at ACAD (ACADIA PHARMACEUTICALS INC) as CEO; HRTX (HERON THERAPEUTICS, INC. /DE/); BLCM (BELLICUM PHARMACEUTICALS, INC). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.